Heart failure with preserved ejection fraction
DOI:
https://doi.org/10.17533/udea.iatreia.26740Keywords:
guideline, heart failure, hypertensionAbstract
Introduction: Heart failure with preserved ejection fraction (EF) is defined as the presence of signs and symptoms of this disease with an EF ≥ 40 % and myocardial structural or functional impairment.
Methodology: We followed the steps defined in the Methodological Guide for the Preparation of Clinical Practice Guidelines and Economic Evaluation in the General System of Social Security of the Colombian Ministry of Health and Social Protection, to develop clinical practice guidelines based on evidence (GPC).
Results: In this issue we present the recommendations to treat heart failure with preserved ejection fraction.
Conclusion: Advances in the treatment of heart failure with reduced ejection fraction have not shown a similar effect in patients with preserved EF. Specific recommendations for the treatment of these patients are established.
Downloads
References
(1.) Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006 Jul;355(3):251-9.
(2.) Huang D, Cheng JW. Pharmacologic management of heart failure with preserved ejection fraction. Ann Pharmacother. 2010 Dec;44(12):1933-45. DOI 10.1345/aph.1P372.
(3.) van Veldhuisen DJ, Cohen-Solal A, Böhm M, Anker SD, Babalis D, Roughton M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol. 2009 Jun;53(23):2150-8. DOI 10.1016/j.jacc.2009.02.046.
(4.) Yamamoto K, Origasa H, Hori M; J-DHF Investigators. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail. 2013 Jan;15(1):110-8. DOI 10.1093/eurjhf/hfs141.
(5.) Liu F, Chen Y, Feng X, Teng Z, Yuan Y, Bin J. Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis. PLoS One. 2014 Mar;9(3):e90555. DOI 10.1371/journal.pone.0090555.
(6.) Zi M, Carmichael N, Lye M. The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovasc Drugs Ther. 2003 Mar;17(2):133-9.
(7.) Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006 Oct;27(19):2338-45.
(8.) Fu M, Zhou J, Sun A, Zhang S, Zhang C, Zou Y, et al. Efficacy of ACE inhibitors in chronic heart failure with preserved ejection fraction--a meta analysis of 7 prospective clinical studies. Int J Cardiol. 2012 Feb;155(1):33-8. DOI 10.1016/j.ijcard.2011.01.081.
(9.) Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003 Sep;362(9386):777-81.
(10.) Massie BM, Carson PE, McMurray JJ, Komajda M, Mc-Kelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008 Dec;359(23):2456-67. DOI 10.1056/NEJMoa0805450.
(11.) Heran BS, Musini VM, Bassett K, Taylor RS, Wright JM. Angiotensin receptor blockers for heart failure. Cochrane Database Syst Rev. 2012 Apr;(4):CD003040. DOI 10.1002/14651858.CD003040.pub2.
(12.) Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014 Apr;370(15):1383-92. DOI 10.1056/NEJMoa1313731.
(13.) Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013 Feb;309(8):781-91. DOI 10.1001/jama.2013.905.
(14.) Hashim T, Elbaz S, Patel K, Morgan CJ, Fonarow GC, Fleg JL, et al Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failure. Am J Med. 2014 Feb;127(2):132-9. DOI 10.1016/j.amjmed.2013.08.006.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Iatreia
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Papers published in the journal are available for use under the Creative Commons license, specifically Attribution-NonCommercial-ShareAlike 4.0 International.
The papers must be unpublished and sent exclusively to the Journal Iatreia; the author uploading the contribution is required to submit two fully completed formats: article submission and authorship responsibility.
